Streetbeat News

CING

Cingulate Inc.

https://www.cingulate.com

Industry

Biotechnology

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Open

3.29

Mkt cap

11M

Volume

136K

High

3.57

P/E Ratio

-0.01

52-wk high

152.40

Low

3.29

Div yield

N/A

52-wk low

1.80

The FDA has cleared Cingulate to file for marketing approval of CTx-1301, a treatment for ADHD. Phase 3 data collected so far is sufficient for a New Drug Application. CTx-1301 could benefit over 60% of ADHD patients currently using immediate-release booster doses. Cingulate is advancing discussions with commercialization partners and is ready to engage with payers for reimbursement and market access.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 1:21 pm

As of March 31, 2024, Cingulate reported having $1.1M in cash and cash equivalents. The management is actively seeking opportunities to access additional capital as needed.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 11:34 am

Cingulate reported a Q4 2023 GAAP EPS of $(0.60), which may not be directly comparable to the estimated $(4.86).

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 11:33 am

The article reports on the performance of health care stocks during Wednesday's intraday session, highlighting significant gainers and losers. ThermoGenesis Holdings led the gainers with a 39.0% increase, while CytoMed Therapeutics experienced the largest decline at 29.3%. The report provides insights into the stock movements and market capitalization of these companies.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 5:31 pm

Cingulate (NYSE:CING) has seen a significant decrease in short interest, with a 70.09% drop since the last report, representing 9.81% of its float. This decrease in short interest could indicate a more bullish sentiment towards CING, despite it having a higher short interest than its peers, where the average is 4.16%. The current short interest suggests it would take about 1 day to cover all short positions, based on recent trading volumes.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 2:45 pm

U.S. stocks saw gains with the S&P 500 up 1.20%, Nasdaq up 1.81%, and Dow up 0.49%. Amazon's Q4 results exceeded expectations, projecting Q1 revenue between $138 billion and $143.5 billion. Intelligent Bio Solutions, Tyra Biosciences, and Meta Platforms reported significant stock increases due to positive financial news. Conversely, Cingulate, Atlassian Corporation, and GRI Bio saw their stocks decline following public offering announcements and financial results.

Portfolio Pulse from Avi Kapoor

February 02, 2024 | 7:32 pm

Skechers U.S.A., Inc. (SKX) shares fell by approximately 7% after reporting mixed Q4 financial results, missing revenue estimates but beating EPS expectations. Other stocks showed significant movement, with notable gainers including Intelligent Bio Solutions Inc. (INBS), Meta Platforms, Inc. (META), and Deckers Outdoor Corporation (DECK), among others. Losers included Cingulate Inc. (CING), MedAvail Holdings, Inc. (MDVL), and Scienjoy Holding Corporation (SJ), with various reasons for their declines.

Portfolio Pulse from Avi Kapoor

February 02, 2024 | 6:18 pm

In Friday's intraday session, several healthcare stocks experienced significant movements. Intelligent Bio Solutions (INBS) saw a notable increase of 108.5%, while Atara Biotherapeutics (ATRA) rose by 51.8%. On the downside, Cingulate (CING) dropped by 52.1%, and Biofrontera (BFRI) fell by 35.59%. These movements reflect the volatile nature of healthcare stocks in the market.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 5:31 pm

Cingulate's stock price has decreased following the announcement of a $7.5 million public offering.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 5:25 pm

Nasdaq rose over 200 points with Apple posting upbeat earnings, leading to a positive trend in U.S. stocks. Apple reported Q1 earnings surpassing expectations with record Services and iPhone revenue, despite a decline in China. Other notable movements included Intelligent Bio Solutions and Tyra Biosciences experiencing significant gains, while Cingulate, Gen Digital, and GRI Bio saw sharp declines. Meta Platforms also reported strong Q4 results and announced a new dividend.

Portfolio Pulse from Avi Kapoor

February 02, 2024 | 5:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.